课题基金 / 基金详情

项目摘要

项目成果

Steven Lynn Kunkel的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Chronic interstitial lung disease is observed in a variety of disorders, including infectious diseases, autoimmune disorders of connective tissue, and disorders where the etiology is unknown, such as idiopathic pulmonary fibrosis. While the etiology and mechanism of progression of many of these lung disorders are not known, the exacerbated progression of the disease may be dictated by the host responding to a subsequent pathogen superimposed on the initial etiologic agent. This "second hit" triggers a dynamic interaction in the lung between the inciting agent, immune cells, and structural cells of the lung, culminating in fibroblast activation, proliferation and fibrosis. Understanding the mechanisms responsible for the exacerbation and progression of lung disease chronicity and fibrosis are the broad, long-term objectives of this application. We hypothesize that the host's response to a persistent etiologic agent may predispose lung tissue to an environment of reparative and immunoregulatory cytokines, placing the lungs at risk for a viral infection, which mechanistically contributes to disease chronicity by maintaining a unique cytokine phenotype, altering dendritic cell function, and driving fibroblast activation. We have designed experiments to test this hypothesis and determine if the progression and maintenance of chronic lung inflammation are infuenced by the cytokine phenotype and the host's response to a subsequent viral pathogen superimposed on the initial etiologic agent, constituting a "two hit" mechanism for disease progression. We will focus on mechanisms which lead to a minimally fibrotic lung lesion, induced by type 1 cytokines, versus a fibrotic response, induced by type 2 cytokines, and determine their impact on a subsequent challenging with murine gammaherpesvirus (MHV68). Our specific Aims include: 1) To assess the mechanism(s) whereby MHV68 infection alone or superimposed on a polarized cytokine phenotype alters the host response and subsequent lung pathology in experimental models of chronic lung inflammation; 2) To determine the mechanistic contribution of an MHV68-derived gene product on the evolving chronic lung pathology associated with a type 1 or type 2 cytokine tissue phenotype; and 3) To assess the mechanistic contribution of dendritic cell subsets during MHV68 infection to the chronicity and fibrosis of the lung response in animals with developing type 1 or type 2 cytokine phenotypes.
期刊论文(9)
专著(0)
科研奖励(0)
会议论文
DOI: 10.1016/j.intimp.2011.07.004
发表时间: 2011-11
期刊: International immunopharmacology
影响因子: 5.6
作者: [G. Tarrasón;M. Aulí;Sanam Mustafa;V. Dolgachev;M. T. Domenech;N. Prats;María Domínguez;Rosa López;Nuria Aguilar;M. Calbet;M. Pont;G. Milligan;S. Kunkel;N. Godessart]
通讯作者: G. Tarrasón;M. Aulí;Sanam Mustafa;V. Dolgachev;M. T. Domenech;N. Prats;María Domínguez;Rosa López;Nuria Aguilar;M. Calbet;M. Pont;G. Milligan;S. Kunkel;N. Godessart
DOI: 10.4049/jimmunol.1302766
发表时间: 2014-04-15
期刊: Journal of immunology (Baltimore, Md. : 1950)
影响因子: --
作者: [Shibata T, Habiel DM, Coelho AL, Kunkel SL, Lukacs NW, Hogaboam CM]
通讯作者: Hogaboam CM
Viral disruption of olfactory progenitors is exacerbated in allergic mice.
在过敏小鼠中,病毒对嗅觉祖细胞的破坏更加严重。
DOI: 10.1016/j.intimp.2014.06.034
发表时间: 2014
期刊: International immunopharmacology
影响因子: 5.6
作者: [Ueha,R, Mukherjee,S, Ueha,S, deAlmeidaNagata,DE, Sakamoto,T, Kondo,K, Yamasoba,T, Lukacs,NW, Kunkel,SL]
通讯作者: Kunkel,SL
DOI: 10.4049/immunohorizons.2300001
发表时间: 2023-02-01
期刊: ImmunoHorizons
影响因子: --
作者: [Kimura S, Dupee Z, Lima F, Allen R, Kazmi S, Diodati N, Lukacs NW, Kunkel SL, Schaller M]
通讯作者: Schaller M
6
    The Immune Response to Pathogens is Controlled by the Cytokine-Induced Epigenetics Signature
    Research Training in Experimental Immunology
    Cytokine Phenotypes After the Host's Response During Chronic Lung Inflammation
    Cytokine Phenotypes After the Host's Response During Chronic Lung Inflammation
    国内基金
    海外基金
    Autoimmune diseases therapies: variations on the microbiome in rheumatoid arthritis